A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5 and 5 microgram Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 microgram Twice Daily) Over 24 Weeks in Moderate Persistent Asthma I

Trial Profile

A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5 and 5 microgram Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 microgram Twice Daily) Over 24 Weeks in Moderate Persistent Asthma I

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Tiotropium bromide (Primary) ; Salmeterol
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms MezzoTinA-asthma-1; MezzoTinA-asthma-I
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results of clinical outcome data from five phase III studies (GraziaTinA-asthma, MezzoTinA-asthma-1, MezzoTinA-asthma-2, RubaTinA-asthma and PensieTinA-asthma) presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results of a subgroup analysis assessing FEV1 responses in patients aged <65 and ≥65 years from four randomised trials (PrimoTinA-asthma and MezzoTinA-asthma) presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results of subgroup analysis of five phase III studies presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top